menu

Loading...

AGEN Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

3.360

Open

3.200

VWAP

3.28

Vol

298.90K

Mkt Cap

120.71M

Low

3.150

Amount

981.38K

EV/EBITDA(TTM)

--

Total Shares

36.14M

EV

439.97M

EV/OCF(TTM)

--

P/S(TTM)

0.85

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Show More

Events Timeline

(ET)

2025-12-23

08:20:00

Agenus Publishes Ovarian Cancer Trial Results

2025-11-18 (ET)

2025-11-18

09:34:08

Agenus names Jose Iglesias as Chief Medical Affairs Officer

2025-11-10 (ET)

2025-11-10

08:03:06

Agenus Announces Q3 Earnings Per Share of $1.94, Below Consensus Estimate of $2.20

2025-10-17 (ET)

2025-10-17

08:09:17

Agenus Reveals New Findings from its BOT/BAL at ESMO 2025

2025-06-17 (ET)

2025-06-17

07:39:36

Agenus, Noetik announce research collaboration to develop predictive biomarkers

2025-06-03 (ET)

2025-06-03

08:10:49

Agenus selling U.S. manufacturing facilities to Zydus

2025-06-03

07:15:29

Agenus, Zydus enter $141M collaboration for BOT/BAL production orders

News

Businesswire

02-19Businesswire

Agenus Unveils New Clinical Data on Botensilimab and Balstilimab

Newsfilter

02-19Newsfilter

Agenus' New Therapy Significantly Improves Survival Rates in Cancer Patients

Newsfilter

02-09Newsfilter

Agenus Advances Immunotherapy with Botensilimab Data Presentation

Businesswire

01-20Businesswire

Agenus Announces First Stakeholder Webcast of 2026 Focused on BOT+BAL Program

PRnewswire

01-15PRnewswire

Zydus Lifesciences Closes Acquisition of Agenus Assets, Establishes Zylidac Bio LLC

Newsfilter

01-15Newsfilter

Zydus Lifesciences Closes Acquisition of Agenus Assets, Establishes Zylidac Bio LLC

1 Analyst Rating

Wall Street analysts forecast AGEN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

23.00

Averages

23.00

High

23.00

Current: 0.000

Low

23.00

Averages

23.00

High

23.00

H.C. Wainwright

H.C. Wainwright

Neutral -> Buy

upgrade

$25

AI Analysis

2025-06-04

Reason

H.C. Wainwright

H.C. Wainwright

Price Target

$25

AI Analysis

2025-06-04

upgrade

Neutral -> Buy

Reason

H.C. Wainwright upgraded Agenus to Buy from Neutral with a $25 price target after the company entered into a strategic collaboration with Indian multinational pharmaceutical company Zydus Lifesciences. The definitive partnership is valued at up to $141M and is aimed at accelerating the clinical development of botensilimab and balstilimab while also securing scaled manufacturing both domestically and outside the U.S., the analyst tells investors in a research note. Th firm says that given Agenus' commitment to reducing its cash burn and the capital provided from this partnership, it now believes the company has sufficient funding to advance botensilimab and balstilimab through a Phase 3 trial initiating in the second half of 2025.

Baird

Baird

Neutral

maintain

$4 -> $6

2025-06-04

Reason

Baird

Baird

Price Target

$4 -> $6

2025-06-04

maintain

Neutral

Reason

Baird raised the firm's price target on Agenus to $6 from $4 and keeps a Neutral rating on the shares. The firm updatedits model following the receipt of ts $91M upfront payment from its strategic collaboration with Zydus.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AGEN

Unlock Now

Valuation Metrics

The current forward P/E ratio for Agenus Inc (AGEN.O) is 24.53, compared to its 5-year average forward P/E of -1.24. For a more detailed relative valuation and DCF analysis to assess Agenus Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-1.24

Current PE

24.53

Overvalued PE

14.90

Undervalued PE

-17.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-0.69

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.69

Undervalued EV/EBITDA

-2.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

4.98

Current PS

0.54

Overvalued PS

10.33

Undervalued PS

-0.37

Financials

AI Analysis

Annual

Quarterly

Whales Holding AGEN

Trading Trends

People Also Watch

Frequently Asked Questions

What is Agenus Inc (AGEN) stock price today?

The current price of AGEN is 3.34 USD — it has increased 0.3

What is Agenus Inc (AGEN)'s business?

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

What is the price predicton of AGEN Stock?

Wall Street analysts forecast AGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AGEN is23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Agenus Inc (AGEN)'s revenue for the last quarter?

Agenus Inc revenue for the last quarter amounts to 30.23M USD, increased 20.40

What is Agenus Inc (AGEN)'s earnings per share (EPS) for the last quarter?

Agenus Inc. EPS for the last quarter amounts to 1.94 USD, decreased -162.99

How many employees does Agenus Inc (AGEN). have?

Agenus Inc (AGEN) has 316 emplpoyees as of March 03 2026.

What is Agenus Inc (AGEN) market cap?

Today AGEN has the market capitalization of 120.71M USD.